Evidence from a variety of sources suggests that the neurotransmitter serotonin may have a role in
HSDD by acting excessively as a sexual satiety signal. Serotonergic agents such as the selective
serotonin reuptake inhibitors (SSRIs) inhibit all phases of sex including desire, arousal, and
orgasm. Addition of the 5-HT1A receptor partial agonist, buspirone, to SSRI treatment has been
shown to counteract these negative sexual side effects. The 5-HT1A receptor mediates inhibitory
neurotransmission. Flibanserin, as a full 5-HT1A receptor agonist, is presumed to have similar or
even more pronounced pro-sexual effects as buspirone.